Vyant Bio, Inc. (VYNT)
Market Cap | 1.08M |
Revenue (ttm) | 666,000 |
Net Income (ttm) | -28.71M |
Shares Out | 6.33M |
EPS (ttm) | -4.90 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 47,080 |
Open | 0.177 |
Previous Close | 0.167 |
Day's Range | 0.170 - 0.180 |
52-Week Range | 0.141 - 3.000 |
Beta | 0.55 |
Analysts | Hold |
Price Target | n/a |
Earnings Date | Aug 29, 2023 |
About VYNT
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey. [Read more]
Financial Performance
In 2022, Vyant Bio's revenue was $666,000, a decrease of -41.99% compared to the previous year's $1.15 million. Losses were -$22.69 million, -50.78% less than in 2021.
Financial StatementsNews

Vyant Bio Announces Adjournment of Special Meeting of Stockholders
CHERRY HILL, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 28, 2023 (the “Speci...

AxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio's StemoniX Assets
—Combines Three Leading Human Biomimetic Organoid Platform Technologies for Neurological Drug Discovery— —AxoSim Gains microBrain™ Intellectual Property from StemoniX, Along With Expert Scientific Tea...

Vyant Bio Announces Filing of Form 25 for Voluntary Nasdaq Delisting and SEC Deregistration
CHERRY HILL, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is a biotechnology company that incorporates innovative biology and data science to improv...

Vyant Bio Announces Voluntary Nasdaq Delisting and SEC Deregistration
CHERRY HILL, N.J., April 24, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is a biotechnology company that incorporates innovative biology and data science to impr...

Oxford Nanopore and 4bases Announce Collaboration to Combine Nanopore Sequencing Devices and 4bases Kits to Support Rapid, High-accuracy Analyses in Human and Cancer Genetics, with a First Target of Same-day BRCA1 and BRCA2 Analysis
OXFORD, England--(BUSINESS WIRE)--Oxford Nanopore Technologies plc (Oxford Nanopore) and 4bases, a Switzerland-based company, specialising in kits for sequencing and bioinformatic tools, today announc...

Vyant Bio Commences a Cash Preservation Plan Including a Reduction in Force
Continu ing to E xplore S trategic A lternatives

Vyant Bio Engages LifeSci Capital to Explore Strategic Alternatives
CHERRY HILL, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelo...

Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at Neuroscience 2022 Hosted by the Society for Neuroscience
“Targeting specific functional rescue in a Rett patient cortical organoid disease model”

Vyant Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelo...

Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at the 2022 CDKL5 Forum Hosted by the Loulou Foundation
CHERRY HILL, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelo...

Vyant Bio Teams Up with the International Rett Syndrome Foundation to Host Local Viewing Party in Honor of the 3rd Annual ‘Raise a Glass for Rett Gala'
Charity Event to Drive Awareness and Support Rett Families Around the World

Reaction Biology and Vyant Bio Announce Closing of Definitive Agreement to Acquire U.S. Operations of Vyant Bio, Inc. Subsidiary
~ Reaction Biology Acquire s the Hershey, Pennsylvania-Based U.S. Operations of Vyant Bio Subsidiary vivoPharm PTY Ltd. ~

Vyant Bio Announces Participation at the 2022 CDKL5 Forum Hosted by the Loulou Foundation on November 7-8, 2022
P latform and P oster Presentation s on Vyant Bio's Human First Drug Discovery Platform and Progress on CDKL5 Deficiency Disorder (CDD)

Vyant Bio to Present at the LD Micro Main Event XV on Wednesday, October 26, 2022
- To Discuss its Novel Drug Discovery Platform that i s A ccelerat ing the P rocess of F inding C ures for N eurogenerative D iseases

Vyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference
CHERRY HILL, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelo...

Vyant Bio Reports Second Quarter and First Half 2022 Results and Provides Strategic and Business Highlights
Conference Call and Webcast Today at 4:30 pm ET

Vyant Bio Announces Rescheduled Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
CHERRY HILL, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelo...

Vyant Bio Postpones Second Quarter Investor Conference Call and Webcast
CHERRY HILL, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelo...

Vyant Bio Announces Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
CHERRY HILL, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelo...

Vyant Bio to Present at Investor Summit Group's Q3 Virtual Conference
Cherry Hill, New Jersey--(Newsfile Corp. - August 3, 2022) - Vyant Bio, Inc. (NASDAQ: VYNT) ("Vyant Bio" or "Company") is an innovative biotechnology company reinventing drug discovery for complex neu...

Vyant Bio Retains Skyline Corporate Communications Group, LLC to Provide Investor Relations Services
CHERRY HILL, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelo...

Vyant Bio Reports First Quarter 2022 Results and Provides Strategic and Business Highlights
Conference Call and Webcast Today at 4:30 pm ET

Vyant Bio Announces Investor Conference Call and Webcast for the First Quarter 2022
CHERRY HILL, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopme...

Vyant Bio Announces Participation in BioNJ's 12th Annual BioPartnering Conference
CHERRY HILL, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an innovative biotechnology company reinventing drug discovery for complex neurodevelopment...

Vyant Bio Reports Fourth Quarter and Year-End 2021 Results and Provides Strategic and Business Highlights
Highlights